AnaptysBio Inc (ANAB) News

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio...

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping...

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular...

AnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy Approved in U.S.

By Chris Wack AnaptysBio shares were 11% higher after GSK received U.S. Food and Drug Administration approval for a treatment indication using a...

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population...

AnaptysBio Announces Participation in Upcoming Investor Conferences

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology...